BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10098427)

  • 1. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study.
    Koper PC; Stroom JC; van Putten WL; Korevaar GA; Heijmen BJ; Wijnmaalen A; Jansen PP; Hanssens PE; Griep C; Krol AD; Samson MJ; Levendag PC
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):727-34. PubMed ID: 10098427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
    Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
    Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity.
    Pollack A; Zagars GK; Starkschall G; Childress CH; Kopplin S; Boyer AL; Rosen II
    Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):555-64. PubMed ID: 8621278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
    Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.
    Jackson A; Skwarchuk MW; Zelefsky MJ; Cowen DM; Venkatraman ES; Levegrun S; Burman CM; Kutcher GJ; Fuks Z; Liebel SA; Ling CC
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):685-98. PubMed ID: 11172950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.
    Jani AB; Hand CM; Pelizzari CA; Roeske JC; Krauz L; Vijayakumar S
    BMC Cancer; 2003 May; 3():16. PubMed ID: 12744725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.
    Vranova J; Vinakurau S; Richter J; Starec M; Fiserova A; Rosina J
    Radiat Oncol; 2011 Jul; 6():87. PubMed ID: 21794152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.